Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond ...

Trigeminal neuralgia is an uncommon facial pain syndrome affecting a nerve in the head called the trigeminal nerve. It causes repeated episodes of sudden, extreme, electric-shock–like pain on ...

The anticonvulsant fosphenytoin is safe and effective in quickly decreasing pain from sudden attacks of acute trigeminal ...

NeuroOne submits FDA filing early for trigeminal nerve ablation using its OneRF system as the facial pain market sees projected growth to $416 million by 2030.

Atypical trigeminal neuralgia (ATN) is a chronic pain condition characterized by persistent facial pain that does not respond well to conventional medical treatments, often leading to significant ...

NeuroOne (Nasdaq:NMTC) announced today that it filed an FDA 510(k) submission for its trigeminal nerve ablation technology.

vesicles appeared in the dermatome of the second division. The possibility exists, however, that some second-division fibers were inadvertently severed. The correlation between trigeminal nerve ...

a device intended to treat trigeminal neuralgia, a severe and chronic facial pain disorder. The submission was completed earlier than anticipated, noted the company. The OneRF Trigeminal Nerve ...

a chronic pain condition affecting approximately 100,000 people in the U.S. The trigeminal nerve is the main sensory nerve in the face associated with triggering excruciating pain for this condition.

Expanding into facial pain broadens the clinical impact ... we believe there is a potential to generate revenues from trigeminal nerve ablation in late calendar year 2025.” ...

The OneRF trigeminal nerve ablation technology features a minimally invasive surgical procedure that uses radiofrequency (RF) energy to destroy abnormal tissue and relieve severe, chronic pain in the ...

Expanding into facial pain broadens the clinical impact of our technology and further validates the versatility and scalability of our platform.” "If cleared by the FDA, we believe there is a ...